FDA Approves Label Change for Flomax Following Report of Cataract Surgery Complications

11/14/2005   09:48:18 AM

Study Shows Prostate Drug Causes “Intraocular Floppy Iris Syndrome”: Doctors Must Anticipate Using Alternative Surgical Strategies

SAN FRANCISCO, Monday, November 14, 2005 – Who knew that the most commonly prescribed prostate drug may complicate cataract surgery in male patients? David F. Chang, MD and John R. Campbell, MD suspected this after conducting a recently published study that examined the incidence of Intraoperative Floppy Iris Syndrome (IFIS) in their cataract surgery practices.

“Flomax does not affect vision or eye health,” said Dr. Chang. “But it blocks the dilator muscle in the iris, and during cataract surgery, the pupil needs to be dilated.”

Following the announcement of their findings, ophthalmologists were asked to track the incidence of IFIS in cataract patients on Flomax and other prostate drugs, and send reports on verified cases to the Federal Drug Administration. The FDA responded to the doctors concerns and approved a label change for the drugs that reads “The patient’s ophthalmologist should be prepared for possible modifications to their surgical technique.” The Academy has notified its members of the FDA label change regarding the Flomax/IFIS link, and recommended that they thoroughly question their male cataract patients about prostate medications prior to surgery. Other prostate drugs in this class include Hytrin, Cardura, and Uroxatral.

In addition to having a pupil that dilates poorly, a patient with IFIS will have an iris that behaves erratically during cataract surgery. It will tend to be floppy and the pupil may suddenly constrict during the middle of surgery. This increases the risk of having surgical complications. .

Dr. Chang and Dr. Campbell suggest that cataract surgeons inquire specifically about prior use of Flomax as IFIS can occur several years after the drug has been discontinued. 

“The persistence of IFIS long after the discontinuation of Flomax suggests a semi-permanent loss of iris dilator muscle tone,” Dr. Chang said in his paper.

Dr. Chang continues to say that it is not necessary to stop the use of Flomax, but patients should inform their ophthalmologist if they are taking the drug, or any type of prostate medication prior to having eye surgery.

“Flomax is an excellent drug for treating the symptoms of an enlarged prostate, and patients taking it should not worry,” concluded Dr. Chang. “However, prior to cataract surgery, they absolutely need to inform their eye surgeon if they are, or have taken prostate drugs.”

“Being forewarned that the patient is taking Flomax allows the eye surgeon to anticipate the need for special measures during surgery,” he added.

Note to editors: For additional information on the intraocular floppy iris syndrome, please visit Dr. Chang’s Web site at www.changcataract.com  and go to the link for “articles for physicians.”


Please Note: Media relations staff are unable to answer inquiries from the general public. If you want more information on eye health, please visit our partner Web site, the Medem Network, at http://www.aao.org/news/release/www.medem.com/eyehealth. If you want to find an Eye M.D. (ophthalmologist) in your area, please use our Find an Eye M.D. feature.

About Us Academy Jobs Privacy Policy Contact Us Terms of Service Medical Disclaimer Site Index